$SNDX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Syndax Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Syndax Pharmaceuticals Inc. Get notifications about new insider transactions in Syndax Pharmaceuticals Inc for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 2021 | SNDX | Syndax Pharmaceuti ... | Meyers Michael L. | SVP, Chief Medical ... | Buy | P | 15.46 | 500 | 7,730 | 15,666 | 15.2 K to 15.7 K (+3.30 %) |
| Apr 22 2021 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Buy | P | 14.11 | 13,967 | 197,077 | 43,300 | 29.3 K to 43.3 K (+47.62 %) | |
| Mar 03 2021 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | M | 6.35 | 10,167 | 64,560 | 0 | ||
| Mar 03 2021 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | M | 7.20 | 74 | 533 | 0 | ||
| Mar 03 2021 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Sell | S | 24.31 | 74 | 1,799 | 16,000 | 16.1 K to 16 K (-0.46 %) | |
| Mar 03 2021 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Sell | S | 24.31 | 10,167 | 247,182 | 16,074 | 26.2 K to 16.1 K (-38.74 %) | |
| Mar 03 2021 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Buy | M | 7.20 | 74 | 533 | 26,241 | 26.2 K to 26.2 K (+0.28 %) | |
| Mar 03 2021 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Buy | M | 6.35 | 10,167 | 64,560 | 26,167 | 16 K to 26.2 K (+63.54 %) | |
| Feb 10 2021 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Option Exercise | M | 7.20 | 35,156 | 253,123 | 0 | |
| Feb 10 2021 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Sell | S | 20.55 | 35,156 | 722,403 | 48,336 | 83.5 K to 48.3 K (-42.11 %) |
| Feb 10 2021 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Buy | M | 7.20 | 35,156 | 253,123 | 83,492 | 48.3 K to 83.5 K (+72.73 %) |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | A | 21.36 | 160,000 | 3,417,600 | 160,000 | |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Option Exercise | A | 21.36 | 80,000 | 1,708,800 | 80,000 | |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Karydas Daphne | Chief Financial Off ... | Option Exercise | A | 21.36 | 95,000 | 2,029,200 | 95,000 | |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Meury William | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K | |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Legault Pierre | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K | |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K | |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K | |
| Feb 05 2021 | SNDX | Syndax Pharmaceuti ... | Jarrett Jennifer | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K | |
| Feb 03 2021 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | M | 7.20 | 15,000 | 108,000 | 0 | |
| Feb 03 2021 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Sell | S | 20.19 | 15,000 | 302,799 | 17,659 | 32.7 K to 17.7 K (-45.93 %) |
| Feb 03 2021 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Buy | M | 7.20 | 15,000 | 108,000 | 32,659 | 17.7 K to 32.7 K (+84.94 %) |
| Nov 25 2020 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Option Exercise | M | 3.08 | 5,684 | 17,507 | 0 | |
| Nov 25 2020 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Option Exercise | M | 3.08 | 24,288 | 74,807 | 0 | |
| Nov 25 2020 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Sell | S | 22.89 | 16,334 | 373,924 | 0 | 16.3 K to 0 (-100.00 %) |
| Nov 25 2020 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Sell | S | 23.58 | 7,954 | 187,594 | 16,334 | 24.3 K to 16.3 K (-32.75 %) |
| Nov 25 2020 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Sell | S | 23.33 | 5,684 | 132,603 | 24,288 | 30 K to 24.3 K (-18.96 %) |
| Nov 25 2020 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Buy | M | 3.08 | 5,684 | 17,507 | 29,972 | 24.3 K to 30 K (+23.40 %) |
| Nov 25 2020 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Buy | M | 3.08 | 24,288 | 74,807 | 24,288 | 0 to 24.3 K |
| Nov 12 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Option Exercise | M | 7.20 | 17,466 | 125,755 | 0 | |
| Nov 12 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Option Exercise | M | 7.20 | 62,938 | 453,154 | 0 | |
| Nov 12 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Sell | S | 20.06 | 17,466 | 350,312 | 46,565 | 64 K to 46.6 K (-27.28 %) |
| Nov 12 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Buy | M | 7.20 | 17,466 | 125,755 | 64,031 | 46.6 K to 64 K (+37.51 %) |
| Nov 12 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Sell | S | 20.04 | 62,938 | 1,261,265 | 46,565 | 109.5 K to 46.6 K (-57.48 %) |
| Nov 12 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Buy | M | 7.20 | 62,938 | 453,154 | 109,503 | 46.6 K to 109.5 K (+135.16 %) |
| Nov 06 2020 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | M | 7.20 | 100,000 | 720,000 | 0 | |
| Nov 06 2020 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Sell | S | 20.31 | 100,000 | 2,031,410 | 17,659 | 117.7 K to 17.7 K (-84.99 %) |
| Nov 06 2020 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Buy | M | 7.20 | 100,000 | 720,000 | 117,659 | 17.7 K to 117.7 K (+566.28 %) |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | A | 9.47 | 140,000 | 1,325,800 | 140,000 | |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Grant | A | 0.00 | 15,000 | 0 | 17,659 | 2.7 K to 17.7 K (+564.12 %) |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Shea Richard P | Chief Financial Off ... | Option Exercise | A | 9.47 | 43,200 | 409,104 | 43,200 | |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Shea Richard P | Chief Financial Off ... | Buy | J | 7.97 | 1,505 | 11,995 | 7,121 | 5.6 K to 7.1 K (+26.80 %) |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Shea Richard P | Chief Financial Off ... | Buy | J | 4.89 | 1,401 | 6,851 | 5,616 | 4.2 K to 5.6 K (+33.24 %) |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Option Exercise | A | 9.47 | 194,000 | 1,837,180 | 194,000 | |
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 9.47 | 24,000 | 227,280 | 24,000 | ||
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Meury William | Option Exercise | A | 9.47 | 24,000 | 227,280 | 24,000 | ||
| Feb 14 2020 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Option Exercise | A | 9.47 | 44,000 | 416,680 | 44,000 | ||
| Feb 05 2020 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Buy | P | 8.00 | 12,500 | 100,000 | 43,900 | 31.4 K to 43.9 K (+39.81 %) |
| Oct 11 2019 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Buy | P | 5.40 | 11,000 | 59,400 | 31,400 | 20.4 K to 31.4 K (+53.92 %) |
| Jul 08 2019 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | A | 9.15 | 200,000 | 1,830,000 | 200,000 | |
| Jun 12 2019 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Option Exercise | A | 7.88 | 44,000 | 346,720 | 44,000 | ||
| Jun 12 2019 | SNDX | Syndax Pharmaceuti ... | Meury William | Option Exercise | A | 7.88 | 24,000 | 189,120 | 24,000 | ||
| Jun 12 2019 | SNDX | Syndax Pharmaceuti ... | Legault Pierre | Option Exercise | A | 7.88 | 24,000 | 189,120 | 24,000 | ||
| Jun 12 2019 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 7.88 | 24,000 | 189,120 | 24,000 | ||
| Jun 12 2019 | SNDX | Syndax Pharmaceuti ... | Jarrett Jennifer | Option Exercise | A | 7.88 | 24,000 | 189,120 | 24,000 | ||
| Jun 12 2019 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | A | 7.88 | 24,000 | 189,120 | 24,000 | ||
| May 13 2019 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Buy | P | 7.29 | 7,200 | 52,517 | 20,400 | 13.2 K to 20.4 K (+54.55 %) |
| May 13 2019 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Buy | P | 7.56 | 13,200 | 99,726 | 13,200 | 0 to 13.2 K |
| Mar 22 2019 | SNDX | Syndax Pharmaceuti ... | Meyers Michael L. | SVP, Chief Medical ... | Buy | P | 4.87 | 104 | 506 | 7,222 | 7.1 K to 7.2 K (+1.46 %) |
| Mar 22 2019 | SNDX | Syndax Pharmaceuti ... | Meyers Michael L. | SVP, Chief Medical ... | Buy | P | 4.93 | 1,000 | 4,930 | 7,118 | 6.1 K to 7.1 K (+16.35 %) |
| Feb 08 2019 | SNDX | Syndax Pharmaceuti ... | Meyers Michael L. | SVP, Chief Medical ... | Option Exercise | A | 6.38 | 104,325 | 665,594 | 104,325 | |
| Feb 08 2019 | SNDX | Syndax Pharmaceuti ... | Meyers Michael L. | SVP, Chief Medical ... | Buy | J | 4.76 | 3,720 | 17,707 | 6,118 | 2.4 K to 6.1 K (+155.13 %) |
| Feb 08 2019 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | A | 6.38 | 240,000 | 1,531,200 | 240,000 | |
| Feb 08 2019 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Buy | J | 4.76 | 2,659 | 12,657 | 2,659 | 0 to 2.7 K |
| Nov 07 2018 | SNDX | Syndax Pharmaceuti ... | Meyers Michael L. | SVP, Chief Medical ... | Buy | P | 4.79 | 200 | 958 | 2,398 | 2.2 K to 2.4 K (+9.10 %) |
| Sep 27 2018 | SNDX | Syndax Pharmaceuti ... | Jarrett Jennifer | Option Exercise | A | 7.11 | 35,000 | 248,850 | 35,000 | ||
| Sep 27 2018 | SNDX | Syndax Pharmaceuti ... | Meury William | Option Exercise | A | 7.11 | 35,000 | 248,850 | 35,000 | ||
| Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 188,746 | 0 | 188,746 | |
| Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 705,863 | 0 | 705,863 | |
| Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | J | 0.00 | 1,105,391 | 0 | 1,105,391 | |
| Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 188,746 | 0 | 85,038 | 273.8 K to 85 K (-68.94 %) |
| Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 705,863 | 0 | 318,021 | 1 M to 318 K (-68.94 %) |
| Jun 20 2018 | SNDX | Syndax Pharmaceuti ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.00 | 1,105,391 | 0 | 498,025 | 1.6 M to 498 K (-68.94 %) |
| May 25 2018 | SNDX | Syndax Pharmaceuti ... | Chen Henry | Option Exercise | A | 8.93 | 14,000 | 125,020 | 14,000 | ||
| May 25 2018 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | A | 8.93 | 14,000 | 125,020 | 14,000 | ||
| May 25 2018 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Option Exercise | A | 8.93 | 14,000 | 125,020 | 14,000 | ||
| May 25 2018 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 8.93 | 14,000 | 125,020 | 14,000 | ||
| May 25 2018 | SNDX | Syndax Pharmaceuti ... | Legault Pierre | Option Exercise | A | 8.93 | 14,000 | 125,020 | 14,000 | ||
| May 25 2018 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Option Exercise | A | 8.93 | 14,000 | 125,020 | 14,000 | ||
| Mar 05 2018 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | A | 9.40 | 125,000 | 1,175,000 | 125,000 | |
| Feb 12 2018 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Option Exercise | A | 9.63 | 10,000 | 96,300 | 10,000 | ||
| Feb 12 2018 | SNDX | Syndax Pharmaceuti ... | Legault Pierre | Option Exercise | A | 9.63 | 10,000 | 96,300 | 10,000 | ||
| Feb 12 2018 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 9.63 | 10,000 | 96,300 | 10,000 | ||
| Feb 12 2018 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Option Exercise | A | 9.63 | 10,000 | 96,300 | 10,000 | ||
| Feb 12 2018 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | A | 9.63 | 10,000 | 96,300 | 10,000 | ||
| Feb 12 2018 | SNDX | Syndax Pharmaceuti ... | Chen Henry | Option Exercise | A | 9.63 | 10,000 | 96,300 | 10,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Option Exercise | M | 3.08 | 732 | 2,255 | 0 | |
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Sell | S | 15.00 | 5,000 | 75,000 | 0 | 5 K to 0 (-100.00 %) |
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Buy | M | 3.08 | 732 | 2,255 | 5,000 | 4.3 K to 5 K (+17.15 %) |
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Sledge George W. Jr. | Option Exercise | A | 13.58 | 5,000 | 67,900 | 5,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Option Exercise | A | 13.58 | 5,000 | 67,900 | 5,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Option Exercise | A | 13.58 | 10,000 | 135,800 | 10,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Legault Pierre | Option Exercise | A | 13.58 | 5,000 | 67,900 | 5,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Legault Pierre | Option Exercise | A | 13.58 | 10,000 | 135,800 | 10,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 13.58 | 10,000 | 135,800 | 10,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Option Exercise | A | 13.58 | 5,000 | 67,900 | 5,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Option Exercise | A | 13.58 | 10,000 | 135,800 | 10,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | A | 13.58 | 5,000 | 67,900 | 5,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | A | 13.58 | 10,000 | 135,800 | 10,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Chen Henry | Option Exercise | A | 13.58 | 5,000 | 67,900 | 5,000 | ||
| May 19 2017 | SNDX | Syndax Pharmaceuti ... | Chen Henry | Option Exercise | A | 13.58 | 10,000 | 135,800 | 10,000 | ||
| Mar 31 2017 | SNDX | Syndax Pharmaceuti ... | Katkin Keith | Option Exercise | A | 13.78 | 25,000 | 344,500 | 25,000 | ||
| Mar 22 2017 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Sell | D | 13.75 | 125,000 | 1,718,750 | 625,545 | 750.5 K to 625.5 K (-16.65 %) | |
| Feb 15 2017 | SNDX | Syndax Pharmaceuti ... | Shea Richard P | Chief Financial Off ... | Option Exercise | A | 10.20 | 125,000 | 1,275,000 | 125,000 | |
| Feb 08 2017 | SNDX | Syndax Pharmaceuti ... | Ordentlich Peter | Chief Scientific Of ... | Option Exercise | A | 8.77 | 20,000 | 175,400 | 20,000 | |
| Feb 08 2017 | SNDX | Syndax Pharmaceuti ... | Morrison Briggs | Chief Executive Off ... | Option Exercise | A | 8.77 | 160,000 | 1,403,200 | 160,000 | |
| Feb 08 2017 | SNDX | Syndax Pharmaceuti ... | Meyers Michael L. | SVP, Chief Medical ... | Option Exercise | A | 8.77 | 66,100 | 579,697 | 66,100 | |
| Feb 08 2017 | SNDX | Syndax Pharmaceuti ... | Metzger Michael A | President and COO | Option Exercise | A | 8.77 | 95,000 | 833,150 | 95,000 | |
| Jan 05 2017 | SNDX | Syndax Pharmaceuti ... | Legault Pierre | Option Exercise | A | 7.08 | 20,000 | 141,600 | 20,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | Chen Henry | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | Sledge George W. Jr. | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | Shea Richard P | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | Podlesak Dennis | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | Egros Fabrice | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | ||
| Nov 02 2016 | SNDX | Syndax Pharmaceuti ... | Kamdar Kim P. | Director | Option Exercise | A | 11.81 | 8,000 | 94,480 | 8,000 | |
| Mar 09 2016 | SNDX | Syndax Pharmaceuti ... | MPM BioVentures IV QP LP | 10% Owner | Option Exercise | C | 0.00 | 312,085 | 0 | 0 | |
| Mar 09 2016 | SNDX | Syndax Pharmaceuti ... | MPM BioVentures IV QP LP | 10% Owner | Option Exercise | C | 0.00 | 718,396 | 0 | 0 | |
| Mar 09 2016 | SNDX | Syndax Pharmaceuti ... | MPM BioVentures IV QP LP | 10% Owner | Option Exercise | C | 0.00 | 1,138,210 | 0 | 0 | |
| Mar 09 2016 | SNDX | Syndax Pharmaceuti ... | MPM BioVentures IV QP LP | 10% Owner | Buy | C | 0.00 | 312,085 | 0 | 2,168,691 | 1.9 M to 2.2 M (+16.81 %) |
| Mar 09 2016 | SNDX | Syndax Pharmaceuti ... | MPM BioVentures IV QP LP | 10% Owner | Buy | C | 0.00 | 718,396 | 0 | 1,856,606 | 1.1 M to 1.9 M (+63.12 %) |
| Mar 09 2016 | SNDX | Syndax Pharmaceuti ... | MPM BioVentures IV QP LP | 10% Owner | Buy | C | 0.00 | 1,138,210 | 0 | 1,138,210 | 0 to 1.1 M |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Director | Option Exercise | C | 0.00 | 86,419 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Director | Option Exercise | C | 0.00 | 198,931 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Director | Option Exercise | C | 0.00 | 315,195 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Director | Buy | P | 12.00 | 150,000 | 1,800,000 | 750,545 | 600.5 K to 750.5 K (+24.98 %) |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Director | Buy | C | 0.00 | 86,419 | 0 | 600,545 | 514.1 K to 600.5 K (+16.81 %) |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Director | Buy | C | 0.00 | 198,931 | 0 | 514,126 | 315.2 K to 514.1 K (+63.11 %) |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | ROYSTON IVOR | Director | Buy | C | 0.00 | 315,195 | 0 | 315,195 | 0 to 315.2 K |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Director | Option Exercise | C | 0.00 | 312,085 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Director | Option Exercise | C | 0.00 | 718,396 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Director | Option Exercise | C | 0.00 | 1,138,210 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Director | Buy | C | 0.00 | 312,085 | 0 | 2,168,691 | 1.9 M to 2.2 M (+16.81 %) |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Director | Buy | C | 0.00 | 718,396 | 0 | 1,856,606 | 1.1 M to 1.9 M (+63.12 %) |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | EVNIN LUKE | Director | Buy | C | 0.00 | 1,138,210 | 0 | 1,138,210 | 0 to 1.1 M |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | DP VI Associates, L.P. | Director | Option Exercise | C | 0.00 | 13,925 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | DP VI Associates, L.P. | Director | Buy | C | 0.00 | 13,925 | 0 | 13,925 | 0 to 13.9 K |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | Domain Partners VI, L.P. | 10% Owner | Option Exercise | C | 0.00 | 444,460 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | Domain Partners VI, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,299,394 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | Domain Partners VI, L.P. | 10% Owner | Buy | C | 0.00 | 1,743,854 | 0 | 1,743,854 | 0 to 1.7 M |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | DP VIII Associates, L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,674 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | DP VIII Associates, L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,967 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | DP VIII Associates, L.P. | 10% Owner | Buy | C | 0.00 | 5,641 | 0 | 5,641 | 0 to 5.6 K |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | Domain Partners VIII, L.P. | 10% Owner | Option Exercise | C | 0.00 | 360,640 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | Domain Partners VIII, L.P. | 10% Owner | Option Exercise | C | 0.00 | 400,422 | 0 | 0 | |
| Mar 08 2016 | SNDX | Syndax Pharmaceuti ... | Domain Partners VIII, L.P. | 10% Owner | Buy | C | 0.00 | 761,062 | 0 | 761,062 | 0 to 761.1 K |
Page: 1